Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients.
Fiche publication
Date publication
avril 2021
Journal
Neuro-oncology practice
Auteurs
Membres identifiés du Cancéropôle Est :
Dr PAGET-BAILLY Sophie, Dr CURTIT Elsa, Dr VERNEREY Dewi
Tous les auteurs :
Garnier L, Charton E, Falcoz A, Paget-Bailly S, Vernerey D, Jary M, Ducray F, Curtit E
Lien Pubmed
Résumé
Randomized controlled trials (RCTs) represent the best evidence in oncology research. Glioblastoma is the most frequent and deadly primary brain tumor, affecting health-related quality of life. An important end point is patient-reported outcomes (PROs). There are no data regarding how well publications of glioblastoma RCTs report PROs. A specific PRO extension of the Consolidated Standards of Reporting Trials (CONSORT) statement was created to improve the quality of reporting. The aim of this study was to evaluate adherence to the CONSORT-PRO statement in reporting RCTs addressing the treatment of patients with glioblastoma. PRO analysis methodology was explored and criteria associated with higher quality of reporting were investigated.
Mots clés
CONSORT-PRO statement, glioblastoma, health-related quality of life, patient-reported outcomes, randomized controlled trials
Référence
Neurooncol Pract. 2021 Apr;8(2):148-159